Tasmar
® (
tolcapone) is a prescription medication used to treat
Parkinson's disease. It is always used in combination with
carbidopa-levodopa products (
Sinemet®,
Sinemet CR, or
Parcopa®), as it is not effective at treating Parkinson's disease without the use of levodopa. Tasmar is useful for people who experience otherwise uncontrollable fluctuations in their symptoms, such as "wearing off" of their
carbidopa-levodopa before each dose.
Due to the risk of potentially fatal liver failure that is sometimes caused by Tasmar, people should only use the drug if other alternatives are not acceptable or do not work.
Tasmar is made by Legacy Pharmaceuticals (for the 100 mg tablets) or Hoffmann-La Roche, Inc. (for the 200 mg tablets) and marketed by Valeant Pharmaceuticals North America.
Tasmar is always used in combination with carbidopa and levodopa; it is not effective at treating Parkinson's disease when used alone. The drug works by increasing blood levels of levodopa and helping it last longer in the body. Tasmar works by inhibiting an enzyme known as catechol-O-methyltransferase (COMT) that breaks down levodopa before it has a chance to reach the brain.